Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Prestige Group to Launch Two Housing Projects in Delhi-NCR in FY26-27; Targets Rs 7,000 Crore Revenue
The total developable area in these two projects would be nearly 8 million sq ft, and the total revenue potential is estimated at Rs 6,800 crore, as per the company's latest investor presentation.
Prestige Group to launch 2 housing projects in Delhi-NCR this fiscal with potential revenue of Rs 7000 crore
Prestige Estates is significantly expanding its presence in Delhi-NCR, planning two new housing projects this fiscal year with an estimated revenue of Rs 6,800 crore. This follows a successful launch last year, which garnered substantial pre-sales. The company is bullish on the market, aiming for Rs 35,000-36,000 crore in sales bookings overall this fiscal, driven by strong customer demand for long-term real estate investments.
Buy, Sell Or Hold: Reliance Industries, Tata Motors CV, DLF, Garden Reach Shipbuilders And Ola Electric — Ask Profit
Market experts shared buy, sell and hold recommendations for an array of stocks.
Cabin crew error costs Japan Airlines CEO 30% salary cut — But it's not new to Japanese corporates
Docking a CEO's salary to show accountability for an employee's mistake is a standard practice in Japanese corporate culture
SEBI reintroduces open market buybacks via stock exchanges from 1 August - Business Standard
SEBI reintroduces open market buybacks via stock exchanges from 1 AugustBusiness Standard
Mahindra Lifespace Developers acquires 15-acre land parcel in Kandivali East, Mumbai
With estimated gross development value of Rs 5,600 cr
Stanley Lifestyles secures armchair supply order from Infopark Developers
Stanley Lifestyles has received an order from Infopark Developers, a Tata Realty company, for the supply of armchairs for an office area.
SC flags 'deep-rooted nexus' between banks, ARCs, borrowers over loans
Flagging a deep-rooted nexus between banks, asset reconstruction companies and borrowers, the Supreme Court on Friday said that taxpayers' money being given as loans and then no effective efforts were taken to recover the amount was not acceptable. A bench of Chief Justice Surya Kant and Justice V Mohana said it was only concerned about the misutilisation of public money, which should have been spent for the welfare of people. The top court issued notice to the Centre, the Reserve Bank of India (RBI) and others seeking their responses on a plea which alleged that a debt of Rs 1,537 crore owed to public sector banks was settled through two asset reconstruction companies (ARCs) for a mere Rs 73.50 crore. During the hearing, the bench raised concerns over the manner in which stressed loans were being settled. "This is a deep-rooted nexus between the borrowers, ARCs and banks," the bench said. The top court observed that it was aware of the limitation in entering into the arena of ...
Mahindra Lifespaces buys 15-acre land in Mumbai to build Rs 5,600 cr housing project
Mahindra Lifespace Developers has secured a prime 15-acre plot in Mumbai's Kandivali East, paving the way for a massive housing project. This development is projected to generate an impressive Rs 5,600 crore in revenue and will span approximately 1.8 million square feet. The acquisition, made through a competitive bid, marks a significant expansion for the realty firm, which boasts a substantial development footprint across India.
Mahindra Lifespaces acquires 15-acre Mumbai land parcel with ₹5,600 crore GDV potential
Shares of Mahindra Lifespace Developers Ltd ended at ₹352.90, up by ₹3.00, or 0.86%, on the BSE.
Alembic Pharma gets tentative nod from USFDA for generic cancer drug
Alembic Pharmaceuticals has secured tentative approval from the USFDA for its generic Binimetinib tablets. This marks a significant step for the company in the cancer treatment drug market. The approval is for the 45mg strength, with potential for marketing exclusivity. Alembic previously received tentative approval for the 15mg strength. Binimetinib is used in combination therapies for melanoma and lung cancer.
Alembic Pharmaceuticals receives USFDA approval for Binimetinib Tablets, 45 mg
Alembic Pharmaceuticals (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Binimetinib Tablets, 45 mg. Alembic had previously received tentative approval for Binimetinib Tablets, 15mg.